Imunon Inc (IMNN) Stock Price, Quote & News

Company Profile

Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non...

Industry: Biotechnology

Sector: Healthcare

Phone: 609 896 9100

Website: imunon.com

Address:

997 Lenox Drive, Suite 100, Lawrenceville, United States

jjegglie Aug. 5 at 7:33 PM

$IMNN Lost in the nonsense statements and double talk we've all come to know and expect from celsion, Sleazy Statborg told you that the cash butn rate is set to soar, just as I told everyone it would. Q2 burn of 2.8 million. Cash on hand 4.7 million end of q2 plus 3.1 million in warrant sales for a total of 7.8 million. But she also said that cash was sufficient "into the 4th quarter" which begins in only 7 weeks. Massive dilution incoming.

0 · Reply

thesouradeep Aug. 5 at 6:55 PM

$IMNN literally no buyers for this stock. This shit is going down

0 · Reply

I_AM_GROOT Aug. 5 at 6:38 PM

$IMNN Weinright and co could be building a short position knowing they will do another placement in addition to an ATM dilutive offering soon. Seems there is way more cash to be made shorting just before the dilutive financing hits. Either placement or ATM will be dilutive regardless. Tick Tock...

0 · Reply

Goldpay55 Aug. 5 at 6:09 PM

$IMNN so the powers that be have decided to hold this at $9. you cannot fight city hall they say.

1 · Reply

thesouradeep Aug. 5 at 5:05 PM

$IMNN such a slow ticker my god lol

0 · Reply

jjegglie Aug. 5 at 4:20 PM

$IMNN You know the propaganda room is running out of ideas when they start pimping their covid headline equity division, Ronco ©️ PLACCINE 🤣🤣

0 · Reply

bb06 Aug. 5 at 3:58 PM

$IMNN Massive dilution ahead...IMNN plans to increase the number of authorized shares from 112M to 350M.

1 · Reply

Groggok Aug. 5 at 3:24 PM

$IMNN On call Stacy L- Continue ‘to prioritize partnerships’ expand institutional investor base’ ,’exploring global: regional partnerships’, ‘ engaging vaccine companies’, etc. As early as this Friday, will achieve Nasdaq compliance on share price’.

0 · Reply

thesouradeep Aug. 5 at 2:49 PM

$IMNN do you like what youre seeing ??

0 · Reply

Groggok Aug. 5 at 1:49 PM

$IMNN I like these key words…’COMMITTED to funding this pivotal trial STRATEGICALLY’.

1 · Reply

IMUNON Recaps Highlights from 2025 Second Quarter Financial Results Conference Call

Aug 5, 2025, 1:26 PM EDT - 11 hours ago

Imunon, Inc. (IMNN) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 8:00 AM EDT - 16 hours ago

IMUNON Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 30, 2025, 8:05 AM EDT - 6 days ago

IMUNON Announces First Patient Dosed in Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

Jul 29, 2025, 8:30 AM EDT - 7 days ago

IMUNON to Hold Second Quarter 2025 Financial Results and Business Update Conference Call on Tuesday, August 5, 2025

Jul 28, 2025, 8:05 AM EDT - 8 days ago

IMUNON Announces Stock Dividend Boosting Shareholder Value

Jul 23, 2025, 8:00 AM EDT - 13 days ago

IMUNON Announces Reverse Stock Split

Jul 15, 2025, 8:05 AM EDT - 21 days ago

IMUNON Granted Continued Listing Extension by Nasdaq to Complete Compliance Plan

Jun 18, 2025, 8:05 AM EDT - 6 weeks ago

IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025

Jun 17, 2025, 8:05 AM EDT - 7 weeks ago

IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™

Jun 3, 2025, 8:05 AM EDT - 2 months ago

IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study

Jun 2, 2025, 8:05 AM EDT - 2 months ago

IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS

May 27, 2025, 8:05 AM EDT - 2 months ago

IMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025

May 23, 2025, 6:59 PM EDT - 2 months ago

IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules

May 23, 2025, 8:05 AM EDT - 2 months ago

IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer

May 22, 2025, 5:20 PM EDT - 2 months ago

IMUNON Announces Withdrawal of Form S-1 Registration Statement

May 15, 2025, 8:05 AM EDT - 2 months ago

IMUNON Announces Six-Month Data Showing Durability of Protection for Next-Generation DNA Vaccine Platform in Phase 1 Clinical Trial in COVID-19

May 12, 2025, 12:56 PM EDT - 3 months ago

Imunon, Inc. (IMNN) Q1 2025 Earnings Call Transcript

May 12, 2025, 8:00 AM EDT - 3 months ago

IMUNON Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 8:05 AM EDT - 3 months ago

IMUNON Announces First Site Initiated for Pivotal Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

May 6, 2025, 8:05 AM EDT - 3 months ago

IMUNON Announces Data from Phase 1/2 Trial Evaluating Intraperitoneal IMNN-001 in Combination with Neoadjuvant Chemotherapy in Newly Diagnosed Patients with Advanced Epithelial Ovarian Cancer to be Published in Gynecologic Oncology

May 5, 2025, 8:00 AM EDT - 3 months ago

IMUNON to Hold First Quarter 2025 Financial Results and Business Update Conference Call on Monday, May 12, 2025

Apr 21, 2025, 8:05 AM EDT - 3 months ago

IMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting

Mar 24, 2025, 8:00 AM EDT - 4 months ago

IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

Feb 27, 2025, 2:32 PM EST - 5 months ago

Imunon, Inc. (IMNN) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 8:05 AM EST - 5 months ago

IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study

Feb 26, 2025, 8:05 AM EST - 5 months ago

IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19

Feb 20, 2025, 8:30 AM EST - 5 months ago

IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025

Feb 19, 2025, 8:05 AM EST - 5 months ago

IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer

Feb 10, 2025, 8:05 AM EST - 6 months ago

IMUNON Appoints Douglas V. Faller, M.D.

Dec 19, 2024, 8:05 AM EST - 8 months ago

IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer

Dec 10, 2024, 8:05 AM EST - 8 months ago

IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001

Nov 25, 2024, 8:05 AM EST - 9 months ago

IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer

Nov 7, 2024, 5:11 PM EST - 9 months ago

Imunon, Inc. (IMNN) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 10:00 AM EST - 9 months ago

IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting

Nov 7, 2024, 8:05 AM EST - 9 months ago

IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates

Oct 31, 2024, 8:30 AM EDT - 9 months ago

IMUNON to Hold Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 7, 2024

Oct 30, 2024, 9:05 AM EDT - 9 months ago

IMUNON to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting

Oct 7, 2024, 8:05 AM EDT - 10 months ago

IMUNON Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Sep 9, 2024, 4:06 PM EDT - 11 months ago

UPDATE - IMUNON's Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management

Aug 28, 2024, 8:30 AM EDT - 1 year ago

IMUNON to Host R&D Day on September 18th

Aug 14, 2024, 2:55 PM EDT - 1 year ago

Imunon, Inc. (IMNN) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 8:00 AM EDT - 1 year ago

IMUNON Reports Second Quarter 2024 Financial Results and Provides a Business Update

Aug 7, 2024, 5:04 PM EDT - 1 year ago

IMUNON to Hold Second Quarter 2024 Financial Results and Business Update Conference Call on Wednesday, August 14, 2024

Jul 30, 2024, 1:07 PM EDT - 1 year ago

Nano-Cap IMUNON's Lead Candidate Shows Overall Survival Of Around 11 Months In Untreated Ovarian Cancer Patients

Jul 30, 2024, 9:42 AM EDT - 1 year ago

Imunon's stock rockets after ovarian cancer treatment's positive trial results

Jul 30, 2024, 8:00 AM EDT - 1 year ago

IMUNON Announces 11.1 Month Increase in Overall Survival in Patients with Newly Diagnosed, Advanced Ovarian Cancer Treated with IMNN-001

Jul 29, 2024, 4:05 PM EDT - 1 year ago

IMUNON to Report Topline Results from the Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer Tomorrow

Jun 24, 2024, 8:30 AM EDT - 1 year ago

IMUNON Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer

Jun 5, 2024, 8:30 AM EDT - 1 year ago

First Participants Vaccinated in IMUNON's IMNN-101 Phase 1 Clinical Trial

jjegglie Aug. 5 at 7:33 PM

0 · Reply

thesouradeep Aug. 5 at 6:55 PM

$IMNN literally no buyers for this stock. This shit is going down

0 · Reply

I_AM_GROOT Aug. 5 at 6:38 PM

0 · Reply

Goldpay55 Aug. 5 at 6:09 PM

$IMNN so the powers that be have decided to hold this at $9. you cannot fight city hall they say.

1 · Reply

thesouradeep Aug. 5 at 5:05 PM

$IMNN such a slow ticker my god lol

0 · Reply

jjegglie Aug. 5 at 4:20 PM

$IMNN You know the propaganda room is running out of ideas when they start pimping their covid headline equity division, Ronco ©️ PLACCINE 🤣🤣

0 · Reply

bb06 Aug. 5 at 3:58 PM

$IMNN Massive dilution ahead...IMNN plans to increase the number of authorized shares from 112M to 350M.

1 · Reply

Groggok Aug. 5 at 3:24 PM

0 · Reply

thesouradeep Aug. 5 at 2:49 PM

$IMNN do you like what youre seeing ??

0 · Reply

Groggok Aug. 5 at 1:49 PM

$IMNN I like these key words…’COMMITTED to funding this pivotal trial STRATEGICALLY’.

1 · Reply

bomber1 Aug. 5 at 1:45 PM

$IMNN They declare and Lindborg supports IMN001; the reality is that the accounts are those of a bankrupt company; the numbers are zero; there is still a long way to go for profitable business; with 10 million in cash!!! After RS and 1 million shares, they don't know what to do anymore!!!! -10% at the opening, makes it clear that the market doesn't listen to words, chatter, promises!!! They want results

0 · Reply

Groggok Aug. 5 at 1:27 PM

$IMNN I like this key word -STRATEGICALLY ‘As we advance the Phase 3 OVATION 3 Study, which will evaluate IMNN-001 in women with stage IIIC or IV ovarian cancer, we are committed to funding this pivotal trial STRATEGICALLY.’

0 · Reply

ConcernedCitizen23 Aug. 5 at 1:11 PM

$IMNN in two days dividend recording date for 15% dividend

1 · Reply

Buysellbkr Aug. 5 at 1:01 PM

$IMNN frm 8.15

0 · Reply

Buysellbkr Aug. 5 at 1:01 PM

$IMNN out 9

0 · Reply

Groggok Aug. 5 at 12:07 PM

$IMNN Our clinical success has attracted increasing interest from potential institutional investors and from potential partners, reflecting confidence in our technology and business strategy. https://finance.yahoo.com/news/imunon-reports-second-quarter-2025-120000108.html

0 · Reply

ConcernedCitizen23 Aug. 5 at 12:51 AM

$IMNN imunon is doing exactly what they’re supposed to do with their trials. Phase 3 trying to confirm phase 2 data.

1 · Reply

MOOSEN Aug. 5 at 12:06 AM

$IMNN TINDY, ALBEIT

0 · Reply

OnlyFibs Aug. 4 at 11:30 PM

$IMNN - recent inflows have been pushing this , zoom out we are trying to fill the other side of the cup, price approching some key levels to claim, gl! #hovdid

0 · Reply

KBernardBio Aug. 4 at 11:05 PM

$IMNN $0.61 (pre split) / $9.20 (post split)

0 · Reply

ConcernedCitizen23 Aug. 4 at 7:58 PM

$IMNN my opinion is that this stock is so cheap it’s outrageous. Phase 2 showed safety which is all it’s supposed to do and this one showed much longer living. Molecular response showed effect too. Phase 3 just started. Should be $500MILL cap…$200/share now…twice as much for buyout. My opinion only. Do what you want.

0 · Reply

Shrekislove69 Aug. 4 at 7:33 PM

$IMNN really wonder if we get anything tomorrow

1 · Reply

Market Cap	19.53M
Revenue (ttm)	0.00
Net Income (ttm)	-18.62M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	133,700
Avg Vol	1,074,329
Day's Range	N/A - N/A
Shares Out	2.12M
Stochastic %K	77%
Beta	2.16
Analysts	Strong Sell
Price Target	$153.67